ZFIN ID: ZDB-FISH-210111-5
Fish name: spint1ahi2217Tg/hi2217Tg
Genotype: spint1ahi2217Tg/hi2217Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by spint1ahi2217Tg/hi2217Tg
Human Disease Conditions Citations
psoriasis standard conditions Martínez-Navarro et al., 2020
GENE EXPRESSION
Gene expression in spint1ahi2217Tg/hi2217Tg
Reporter gene expression No data available
PHENOTYPE
Phenotype in spint1ahi2217Tg/hi2217Tg
Phenotype Conditions Figures
caudal fin ab1-rps6 labeling amount, ameliorated chemical treatment by environment: sirolimus Fig. 2 from Armistead et al., 2020
caudal fin ab1-rps6 labeling amount, ameliorated chemical treatment by environment: EC 3.1.4.* (phosphoric diester hydrolase) inhibitor Fig. 2 from Armistead et al., 2020
caudal fin ab1-rps6 labeling amount, ameliorated chemical treatment by environment: PD 168393 Fig. 2 from Armistead et al., 2020
caudal fin Ab4-egfr labeling amount, ameliorated chemical treatment by environment: PD 168393 Fig. 2 from Armistead et al., 2020
caudal fin mmp9 expression amount, ameliorated chemical treatment by environment: sirolimus Fig. 5 from Armistead et al., 2020
caudal fin mmp9 expression amount, ameliorated chemical treatment by environment: EC 3.1.4.* (phosphoric diester hydrolase) inhibitor Fig. 5 from Armistead et al., 2020
caudal fin mmp9 expression amount, ameliorated chemical treatment by environment: PD 168393 Fig. 5 from Armistead et al., 2020
caudal fin spint1a expression decreased amount, abnormal control Fig. 1 from Armistead et al., 2020
caudal fin ab1-rps6 labeling increased amount, abnormal control Fig. 2 from Armistead et al., 2020
caudal fin Ab4-egfr labeling increased amount, abnormal chemical treatment by environment: sirolimus Fig. 2 from Armistead et al., 2020
caudal fin Ab4-egfr labeling increased amount, abnormal chemical treatment by environment: EC 3.1.4.* (phosphoric diester hydrolase) inhibitor Fig. 2 from Armistead et al., 2020
caudal fin mmp9 expression increased amount, abnormal control Fig. 1Fig. 5 from Armistead et al., 2020
caudal fin Ab4-egfr labeling increased amount, abnormal control Fig. 2 from Armistead et al., 2020
caudal fin cell population proliferation increased occurrence, abnormal chemical treatment by environment: EC 3.1.4.* (phosphoric diester hydrolase) inhibitor Fig. 6 from Armistead et al., 2020
caudal fin cell population proliferation increased occurrence, abnormal control Fig. 1Fig. 2 from Armistead et al., 2020
caudal fin cell population proliferation occurrence, ameliorated chemical treatment by environment: sirolimus Fig. 2 from Armistead et al., 2020
caudal fin cell population proliferation occurrence, ameliorated chemical treatment by environment: EC 3.1.4.* (phosphoric diester hydrolase) inhibitor Fig. 2 from Armistead et al., 2020
caudal fin cell population proliferation occurrence, ameliorated chemical treatment by environment: PD 168393 Fig. 2 from Armistead et al., 2020
caudal fin cell population proliferation occurrence, normal control Fig. 1 from Armistead et al., 2020
caudal fin epidermal basal stratum ab1-lama1 labeling spatial pattern, abnormal control Fig. 5 from Armistead et al., 2020
caudal fin epidermal basal stratum structure, abnormal control Fig. 5 from Armistead et al., 2020
caudal fin epidermal cell aggregated, abnormal control Fig. 1Fig. 2Fig. 6 from Armistead et al., 2020
caudal fin epidermal cell aggregated, abnormal chemical treatment by environment: EC 3.1.4.* (phosphoric diester hydrolase) inhibitor Fig. 6 from Armistead et al., 2020
caudal fin epidermal cell aggregated, ameliorated chemical treatment by environment: sirolimus Fig. 2 from Armistead et al., 2020
caudal fin epidermal cell aggregated, ameliorated chemical treatment by environment: EC 3.1.4.* (phosphoric diester hydrolase) inhibitor Fig. 2Fig. 6 from Armistead et al., 2020
caudal fin epidermal cell aggregated, ameliorated chemical treatment by environment: PD 168393 Fig. 2 from Armistead et al., 2020
caudal fin epidermal cell distributed, normal control Fig. 1Fig. 6 from Armistead et al., 2020
caudal fin keratinocyte increased amount, abnormal standard conditions Fig. 5 from Martínez-Navarro et al., 2020
caudal fin melanocyte amount, ameliorated chemical treatment by environment: pyridoxal 5'-phosphate Fig. 3 from Martínez-Navarro et al., 2020
caudal fin melanocyte increased amount, abnormal standard conditions Fig. 3Fig. 5 from Martínez-Navarro et al., 2020
epidermal basal stratum cell protruding out of epidermis, abnormal standard conditions Fig. 6 from Armistead et al., 2020
epidermal basal stratum cell protruding out of epidermis, ameliorated chemical treatment by environment: EC 3.1.4.* (phosphoric diester hydrolase) inhibitor Fig. 6 from Armistead et al., 2020
epidermal basal stratum cell protruding out of epidermis, ameliorated chemical treatment by environment: EC 2.7.1.91 (sphingosine kinase) inhibitor Fig. 6 from Armistead et al., 2020
keratinocyte cell population proliferation increased occurrence, abnormal chemical treatment by environment: EC 3.1.4.* (phosphoric diester hydrolase) inhibitor Fig. 6 from Armistead et al., 2020
peridermal cell protruding out of epidermis, abnormal standard conditions Fig. 6 from Armistead et al., 2020
peridermal cell protruding out of epidermis, ameliorated chemical treatment by environment: EC 3.1.4.* (phosphoric diester hydrolase) inhibitor Fig. 6 from Armistead et al., 2020
peridermal cell protruding out of epidermis, ameliorated chemical treatment by environment: EC 2.7.1.91 (sphingosine kinase) inhibitor Fig. 6 from Armistead et al., 2020
whole organism life span, normal control Fig. 1 from Armistead et al., 2020

CITATIONS  (2)